Literature DB >> 30447840

Updates on Grading and Staging of Prostate Cancer.

Beth L Braunhut1, Sanoj Punnen2, Oleksandr N Kryvenko3.   

Abstract

Since its development between 1966 and 1977, the Gleason grading system has remained one of the most important prognostic indicators in prostatic acinar adenocarcinoma. The grading system was first majorly revised in 2005 and again in 2014. With the publication of the 8th edition of the American Joint Committee on Cancer TNM staging manual in 2018, the classification of prostate cancer and its reporting have further evolved and are now included as part of staging criteria. This article reflects the aspects that are most influential on daily practice. A brief summary of 3 ancillary commercially available genomic tests is also provided.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gleason grading system; Grade Groups; Prostate cancer; Staging

Mesh:

Year:  2018        PMID: 30447840     DOI: 10.1016/j.path.2018.07.003

Source DB:  PubMed          Journal:  Surg Pathol Clin        ISSN: 1875-9157


  4 in total

1.  Small RNAs as biomarkers to differentiate benign and malign prostate diseases: An alternative for transrectal punch biopsy of the prostate?

Authors:  Lukas Markert; Jonas Holdmann; Claudia Klinger; Michael Kaufmann; Karin Schork; Michael Turewicz; Martin Eisenacher; Andreas Savelsbergh
Journal:  PLoS One       Date:  2021-03-24       Impact factor: 3.240

Review 2.  Acupuncture for pain caused by prostate cancer: Protocol for a systematic review.

Authors:  Jisheng Wang; Yi Lei; Binghao Bao; Xudong Yu; Hengheng Dai; Fei Chen; Haisong Li; Bin Wang
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

3.  Traditional Chinese medicine on treating pain caused by prostate cancer: A systematic review and meta-analysis.

Authors:  Ning Wang; Li Xu; Ji-Sheng Wang; Xu-Dong Yu; Li-Yuan Chu; Sheng Deng; Fu-Xing Ge; Hai-Song Li
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

4.  Assessment of the efficacy of Chinese patent medicine on treating pain caused by prostate cancer: A protocol for systematic review and meta analysis.

Authors:  Xiaoyong Gong; Ji-Sheng Wang; Xu-Dong Yu; Rui-Jia Liu; Li-Yuan Chu; Yuan-Yuan Li; Yi Lei; Hong Li
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.